Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

64Cu SAR bisPSMA - Clarity Pharmaceuticals

Next Previous
Drug Profile

64Cu SAR bisPSMA - Clarity Pharmaceuticals

Alternative Names: 64Cu SAR bisPSMA; Cu-64 SAR-bisPSMA

Latest Information Update: 21 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clarity Pharmaceuticals
  • Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 21 Jul 2025 Clarity Pharmaceuticals completes enrolment in a phase II trial in Prostate cancer (Diagnosis) in Australia (NCT06907641)
  • 17 Jun 2025 Clarity Pharmaceuticals and SpectronRx enters into a manufacturing agreement to produce 64Cu-SAR-bisPSMA
  • 30 May 2025 Efficacy data from a phase I/II COBRA trial in Prostate cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top